
Royalty Pharma PLC
NASDAQ:RPRX

Intrinsic Value
The intrinsic value of one
RPRX
stock under the Base Case scenario is
60.45
USD.
Compared to the current market price of 32.69 USD,
Royalty Pharma PLC
is
Undervalued by 46%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Royalty Pharma PLC
Fundamental Analysis


Revenue & Expenses Breakdown
Royalty Pharma PLC
Balance Sheet Decomposition
Royalty Pharma PLC
Current Assets | 1.8B |
Cash & Short-Term Investments | 1.8B |
Receivables | 23.8m |
Other Current Assets | 3.1m |
Non-Current Assets | 15.8B |
Long-Term Investments | 15.7B |
Other Non-Current Assets | 36.7m |
Free Cash Flow Analysis
Royalty Pharma PLC
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Royalty Pharma PLC
Revenue
|
2.3B
USD
|
Operating Expenses
|
-363.4m
USD
|
Operating Income
|
1.9B
USD
|
Other Expenses
|
-807.8m
USD
|
Net Income
|
1.1B
USD
|
RPRX Profitability Score
Profitability Due Diligence
Royalty Pharma PLC's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

Score
Royalty Pharma PLC's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
RPRX Solvency Score
Solvency Due Diligence
Royalty Pharma PLC's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Score
Royalty Pharma PLC's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RPRX Price Targets Summary
Royalty Pharma PLC
According to Wall Street analysts, the average 1-year price target for
RPRX
is 39.1 USD
with a low forecast of 33.33 USD and a high forecast of 44.1 USD.
Dividends
Current shareholder yield for RPRX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
RPRX
stock under the Base Case scenario is
60.45
USD.
Compared to the current market price of 32.69 USD,
Royalty Pharma PLC
is
Undervalued by 46%.